Close

Ratings by Morgan Stanley (Jeffrey Hung)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
4/2/2024 Disc Medicine IRON Maintain Equalweight
(N/A)
 
 
  Details
3/15/2024 Immuneering Corporation IMRX Maintain Equalweight
(N/A)
 
 
  Details
3/13/2024 Acadia Pharmaceuticals ACAD Maintain Overweight
(N/A)
 
 
  Details
3/8/2024 Disc Medicine IRON Maintain Equalweight
(N/A)
 
 
  Details
3/8/2024 Engene Holdings Inc. ENGN New Coverage Overweight
(N/A)
16.01
(15.40)
-3.81% Details
2/20/2024 CG Oncology CGON New Coverage Overweight
(N/A)
47.46
(39.75)
-16.25% Details
1/16/2024 Crinetics CRNX New Coverage Overweight
(N/A)
37.27
(44.59)
19.64% Details
1/5/2024 Cytokinetics CYTK Downgrade Equalweight
(Overweight)
86.64
(71.56)
-17.41% Details
12/22/2023 Karuna Therapeutics Inc. KRTX Downgrade Equalweight
(Overweight)
215.19
(329.83)
53.27% Details
12/19/2023 Vigil Neuroscience Inc VIGL Downgrade Underweight
(Equalweight)
3.60
(3.22)
-10.56% Details
12/19/2023 Rhythm Pharmaceuticals RYTM Upgrade Overweight
(Equalweight)
47.20
(40.33)
-14.56% Details
12/19/2023 PTC Therapeutics PTCT Downgrade Underweight
(Equalweight)
28.39
(26.42)
-6.94% Details
12/19/2023 Prelude Therapeutics PRLD Downgrade Underweight
(Equalweight)
4.35
(5.62)
29.2% Details
12/19/2023 Invivyd Inc. IVVD Upgrade Equalweight
(Underweight)
1.63
(2.95)
80.98% Details
12/19/2023 Disc Medicine IRON Downgrade Equalweight
(Overweight)
58.72
(31.83)
-45.79% Details
12/19/2023 Amicus Therapeutics FOLD Upgrade Overweight
(Equalweight)
12.72
(10.68)
-16.04% Details
12/19/2023 Acadia Pharmaceuticals ACAD Upgrade Overweight
(Equalweight)
28.58
(17.14)
-40.03% Details
12/8/2023 bluebird bio BLUE Upgrade Equalweight
(Underweight)
4.83
(1.10)
-77.23% Details
11/21/2023 Cytokinetics CYTK Maintain Overweight
(N/A)
 
 
  Details
11/3/2023 Ultragenyx Pharma RARE Maintain Overweight
(N/A)
 
 
  Details
11/3/2023 Bicycle Therapeutics BCYC Maintain Equalweight
(N/A)
 
 
  Details
11/3/2023 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
11/2/2023 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
10/27/2023 PTC Therapeutics PTCT Maintain Equalweight
(N/A)
 
 
  Details
10/10/2023 Ultragenyx Pharma RARE Maintain Overweight
(N/A)
 
 
  Details
9/15/2023 PTC Therapeutics PTCT Maintain Equalweight
(N/A)
 
 
  Details
8/2/2023 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
7/20/2023 Karuna Therapeutics Inc. KRTX New Coverage Overweight
(N/A)
206.83
(329.83)
59.47% Details
7/14/2023 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
7/11/2023 PTC Therapeutics PTCT Maintain Equalweight
(N/A)
 
 
  Details
7/11/2023 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
7/11/2023 Exelixis EXEL New Coverage Equalweight
(N/A)
19.31
(22.81)
18.13% Details
6/12/2023 Disc Medicine IRON Maintain Overweight
(N/A)
 
 
  Details
5/5/2023 Bicycle Therapeutics BCYC Maintain Equalweight
(N/A)
 
 
  Details
4/20/2023 Disc Medicine IRON New Coverage Overweight
(N/A)
25.40
(31.83)
25.31% Details
4/20/2023 Intra-Cellular Therapies ITCI New Coverage Overweight
(N/A)
62.39
(65.88)
5.59% Details
4/19/2023 Immuneering Corporation IMRX Upgrade Equalweight
(Underweight)
12.19
(2.10)
-82.77% Details
4/12/2023 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
3/20/2023 Esperion Therapeutics ESPR Maintain Equalweight
(N/A)
 
 
  Details
3/14/2023 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
3/1/2023 Bicycle Therapeutics BCYC Maintain Equalweight
(N/A)
 
 
  Details
2/28/2023 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
2/27/2023 Esperion Therapeutics ESPR Maintain Equalweight
(N/A)
 
 
  Details
2/27/2023 Repare Therapeutics RPTX Maintain Equalweight
(N/A)
 
 
  Details
2/3/2023 Ultragenyx Pharma RARE Maintain Overweight
(N/A)
 
 
  Details
2/3/2023 PTC Therapeutics PTCT Maintain Equalweight
(Equalweight)
 
 
  Details
2/3/2023 Graphite Bio Inc GRPH Maintain Equalweight
(N/A)
 
 
  Details
2/3/2023 Cullinan Oncology Inc. CGEM Maintain Overweight
(N/A)
 
 
  Details
2/3/2023 Repare Therapeutics RPTX Downgrade Equalweight
(Overweight)
12.60
(3.65)
-71.03% Details
2/3/2023 Neurocrine Bio. NBIX Upgrade Overweight
(Equalweight)
110.22
(134.66)
22.17% Details
2/3/2023 Immuneering Corporation IMRX Downgrade Underweight
(Equalweight)
4.17
(2.10)
-49.64% Details
2/3/2023 Esperion Therapeutics ESPR Upgrade Equalweight
(Underweight)
6.40
(2.14)
-66.56% Details
2/3/2023 Erasca Inc ERAS Upgrade Overweight
(Equalweight)
4.00
(2.11)
-47.25% Details
2/3/2023 Cyteir Therapeutics CYT Downgrade Underweight
(Equalweight)
1.57
(3.02)
92.36% Details
1/30/2023 Celularity CELU Downgrade Underweight
(Equalweight)
0.98
(4.11)
319.39% Details
11/29/2022 Cincor Pharma Inc CINC Downgrade Equalweight
(Overweight)
26.53
(29.06)
9.54% Details
11/2/2022 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
11/2/2022 Esperion Therapeutics ESPR Maintain Underweight
(N/A)
 
 
  Details
11/2/2022 Neurocrine Bio. NBIX Maintain Equalweight
(N/A)
 
 
  Details
9/13/2022 Rubius RUBY Maintain Equalweight
(N/A)
 
 
  Details
9/9/2022 Evofem Biosciences Inc EVFM Maintain Underweight
(N/A)
 
 
  Details
9/9/2022 Celularity CELU Maintain Equalweight
(N/A)
 
 
  Details
9/9/2022 Bicycle Therapeutics BCYC Maintain Equalweight
(N/A)
 
 
  Details
9/9/2022 Prelude Therapeutics PRLD Downgrade Equalweight
(Overweight)
7.56
(5.62)
-25.66% Details
9/9/2022 Cyteir Therapeutics CYT Downgrade Equalweight
(Overweight)
2.10
(3.02)
43.81% Details
9/9/2022 Cincor Pharma Inc CINC Maintain Overweight
(N/A)
 
 
  Details
8/9/2022 Cincor Pharma Inc CINC Maintain Overweight
(N/A)
 
 
  Details
8/9/2022 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
8/8/2022 Repare Therapeutics RPTX Maintain Overweight
(Overweight)
 
 
  Details
6/15/2022 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
5/11/2022 Evofem Biosciences Inc EVFM Maintain Underweight
(N/A)
 
 
  Details
5/11/2022 Rubius RUBY Maintain Equalweight
(N/A)
 
 
  Details
4/18/2022 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
4/12/2022 Evofem Biosciences Inc EVFM Maintain Underweight
(N/A)
 
 
  Details
4/11/2022 Rubius RUBY Maintain Equalweight
(N/A)
 
 
  Details
4/5/2022 Biohaven Pharmaceutical Holding BHVN Maintain Equalweight
(N/A)
 
 
  Details
3/22/2022 Graphite Bio Inc GRPH Downgrade Equalweight
(Overweight)
8.12
(3.18)
-60.84% Details
3/18/2022 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
3/4/2022 Evofem Biosciences Inc EVFM Maintain Underweight
(N/A)
 
 
  Details
3/2/2022 Jazz Pharmaceuticals JAZZ Maintain Equalweight
(N/A)
 
 
  Details
2/14/2022 Bicycle Therapeutics BCYC New Coverage Equalweight
(N/A)
49.02
(22.30)
-54.51% Details
2/11/2022 Ultragenyx Pharma RARE Maintain Overweight
(N/A)
 
 
  Details
2/1/2022 Cincor Pharma Inc CINC New Coverage Overweight
(N/A)
18.11
(29.06)
60.46% Details
12/7/2021 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
11/24/2021 Celularity CELU New Coverage Equalweight
(N/A)
7.15
(4.11)
-42.52% Details
11/16/2021 Evofem Biosciences Inc EVFM Maintain Underweight
(N/A)
 
 
  Details
11/9/2021 Acadia Pharmaceuticals ACAD Maintain Equalweight
(N/A)
 
 
  Details
10/19/2021 Esperion Therapeutics ESPR Maintain Underweight
(N/A)
 
 
  Details
10/19/2021 Rubius RUBY New Coverage Equalweight
(N/A)
16.01
(0.08)
-99.5% Details
10/19/2021 Insmed INSM New Coverage Overweight
(N/A)
26.36
(27.25)
3.38% Details
10/14/2021 Acadia Pharmaceuticals ACAD Downgrade Equalweight
(Overweight)
17.63
(17.14)
-2.78% Details
10/14/2021 Esperion Therapeutics ESPR Downgrade Underweight
(Equalweight)
10.30
(2.14)
-79.22% Details
10/14/2021 Neurocrine Bio. NBIX Downgrade Equalweight
(Overweight)
104.86
(134.66)
28.42% Details
10/14/2021 Evofem Biosciences Inc EVFM Downgrade Underweight
(Equalweight)
0.76
(0.48)
-36.84% Details
10/8/2021 Prelude Therapeutics PRLD Upgrade Overweight
(Equalweight)
17.34
(5.62)
-67.59% Details
10/8/2021 Jazz Pharmaceuticals JAZZ Maintain Equalweight
(N/A)
 
 
  Details
10/8/2021 Cytokinetics CYTK Maintain Overweight
(N/A)
 
 
  Details
9/30/2021 Acceleron Pharma XLRN Downgrade Equalweight
(Overweight)
175.36
(178.75)
1.93% Details
8/13/2021 Repare Therapeutics RPTX Maintain Overweight
(N/A)
 
 
  Details
8/13/2021 Aprea APRE Downgrade Underweight
(Equalweight)
4.10
(5.71)
39.27% Details
8/12/2021 Evofem Biosciences Inc EVFM Maintain Equalweight
(N/A)
 
 
  Details
8/10/2021 Erasca Inc ERAS New Coverage Equalweight
(N/A)
20.99
(2.11)
-89.95% Details
8/9/2021 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
8/6/2021 Aprea APRE Maintain Equalweight
(N/A)
 
 
  Details
8/4/2021 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
8/4/2021 Esperion Therapeutics ESPR Maintain Equalweight
(N/A)
 
 
  Details
7/20/2021 Graphite Bio Inc GRPH New Coverage Overweight
(N/A)
25.81
(8.12)
-68.54% Details
7/13/2021 Cytier Therapeutics CYT New Coverage Overweight
(N/A)
18.89
(3.02)
-84.01% Details
6/7/2021 Cullinan Management CGEM Maintain Overweight
(Overweight)
 
 
  Details
5/10/2021 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
5/6/2021 Neurocrine Bio. NBIX Maintain Overweight
(Overweight)
 
 
  Details
5/6/2021 Acadia Pharmaceuticals ACAD Maintain Overweight
(Overweight)
 
 
  Details
5/5/2021 Ultragenyx Pharma RARE Maintain Overweight
(Overweight)
 
 
  Details
5/5/2021 Esperion Therapeutics ESPR Maintain Equalweight
(Equalweight)
 
 
  Details
4/27/2021 Cullinan Management CGEM Upgrade Overweight
(Equalweight)
31.49
(16.67)
-47.06% Details
4/6/2021 Acadia Pharmaceuticals ACAD Maintain Overweight
(Overweight)
 
 
  Details
3/17/2021 Prelude Therapeutics PRLD Maintain Equalweight
(Equalweight)
 
 
  Details
3/11/2021 Esperion Therapeutics ESPR New Coverage Equalweight
(N/A)
30.06
(2.14)
-92.88% Details
3/9/2021 Acadia Pharmaceuticals ACAD Maintain Overweight
(Overweight)
 
 
  Details
2/26/2021 Acceleron Pharma XLRN Maintain Overweight
(Overweight)
 
 
  Details
2/25/2021 Acadia Pharmaceuticals ACAD Maintain Overweight
(Overweight)
 
 
  Details
2/3/2021 Voyager Therapeutics VYGR Maintain Equalweight
(Equalweight)
 
 
  Details
2/2/2021 Cullinan Management CGEM New Coverage Equalweight
(N/A)
38.01
(16.67)
-56.14% Details
12/29/2020 Aprea APRE Maintain Equalweight
(N/A)
 
 
  Details
12/16/2020 Ultragenyx Pharma RARE Maintain Overweight
(N/A)
 
 
  Details
11/16/2020 Cytokinetics CYTK Maintain Overweight
(N/A)
 
 
  Details
11/12/2020 Prelude Therapeutics PRLD Maintain Equalweight
(N/A)
 
 
  Details
11/10/2020 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
11/6/2020 Acceleron Pharma XLRN Maintain Overweight
(N/A)
 
 
  Details
11/5/2020 Acadia Pharmaceuticals ACAD Maintain Overweight
(N/A)
 
 
  Details
10/12/2020 Cytokinetics CYTK Maintain Overweight
(N/A)
 
 
  Details
9/22/2020 Exelixis exel Maintain Equalweight
(N/A)
 
 
  Details
8/20/2020 Acadia Pharmaceuticals ACAD New Coverage Overweight
(N/A)
39.66
(17.14)
-56.78% Details
8/20/2020 Evofem Biosciences Inc EVFM New Coverage Equalweight
(N/A)
3.35
(0.76)
-77.31% Details
8/4/2020 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
7/15/2020 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
7/15/2020 MyoKardia MYOK Maintain Overweight
(N/A)
 
 
  Details
7/15/2020 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
7/15/2020 Acceleron Pharma XLRN Maintain Overweight
(N/A)
 
 
  Details
5/14/2020 Viela Bio VIE Maintain Overweight
(N/A)
 
 
  Details
5/12/2020 MyoKardia MYOK Maintain Overweight
(N/A)
 
 
  Details
5/12/2020 Cytokinetics CYTK Maintain Overweight
(N/A)
 
 
  Details
5/7/2020 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
5/7/2020 MyoKardia MYOK Maintain Overweight
(N/A)
 
 
  Details
5/6/2020 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
4/9/2020 Cytokinetics CYTK Upgrade Overweight
(Equalweight)
12.15
(71.56)
488.97% Details
3/4/2020 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
2/28/2020 MyoKardia MYOK Maintain Overweight
(N/A)
 
 
  Details
2/3/2020 Acceleron Pharma XLRN Upgrade Overweight
(Equalweight)
86.30
(175.36)
103.2% Details
1/17/2020 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
1/13/2020 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
12/17/2019 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
12/17/2019 Viela Bio VIE Maintain Overweight
(N/A)
 
 
  Details
12/17/2019 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
12/17/2019 MyoKardia MYOK Maintain Overweight
(N/A)
 
 
  Details
12/17/2019 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
12/17/2019 Cytokinetics CYTK Maintain Equalweight
(N/A)
 
 
  Details
12/17/2019 Acceleron Pharma XLRN Maintain Equalweight
(N/A)
 
 
  Details
11/7/2019 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
11/6/2019 Ultragenyx Pharma RARE Maintain Overweight
(N/A)
 
 
  Details
11/5/2019 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
10/31/2019 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
10/28/2019 Viela Bio VIE New Coverage Overweight
(N/A)
19.65
(53.01)
169.77% Details
10/28/2019 Aprea Therapeutics Inc. APRE New Coverage Equalweight
(N/A)
25.70
(4.10)
-84.05% Details
10/11/2019 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
10/11/2019 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
10/11/2019 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
10/11/2019 Acceleron Pharma XLRN Maintain Equalweight
(N/A)
 
 
  Details
9/17/2019 Alder Biopharm ALDR Upgrade Equalweight
(Underweight)
10.06
(18.88)
87.67% Details
8/9/2019 Cytokinetics CYTK Maintain Equalweight
(N/A)
 
 
  Details
8/6/2019 Acceleron Pharma XLRN Maintain Equalweight
(N/A)
 
 
  Details
8/6/2019 Acceleron Pharma XLRN Maintain Equalweight
(N/A)
 
 
  Details
8/1/2019 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
7/15/2019 MyoKardia MYOK Maintain Overweight
(N/A)
 
 
  Details
7/15/2019 Cytokinetics CYTK Maintain Equalweight
(N/A)
 
 
  Details
7/15/2019 Acceleron Pharma XLRN Maintain Equalweight
(N/A)
 
 
  Details
7/12/2019 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
6/17/2019 Ultragenyx Pharma RARE Maintain Overweight
(N/A)
 
 
  Details
5/2/2019 Exelixis EXEL Maintain Equalweight
(N/A)
 
 
  Details
3/18/2019 Exelixis EXEL Upgrade Equalweight
(Underweight)
24.76
(22.81)
-7.88% Details
3/14/2019 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
11/8/2018 Voyager Therapeutics VYGR Maintain Equalweight
(N/A)
 
 
  Details
11/6/2018 Neurocrine Bio. NBIX Maintain Overweight
(N/A)
 
 
  Details
10/29/2018 Ultragenyx Pharma RARE Maintain Equalweight
(N/A)
 
 
  Details
9/10/2018 Ultragenyx Pharma RARE New Coverage Equalweight
(N/A)
84.40
(65.73)
-22.12% Details
9/10/2018 Acceleron Pharma XLRN New Coverage Equalweight
(N/A)
51.09
(178.75)
249.87% Details
9/10/2018 Cytokinetics CYTK New Coverage Equalweight
(N/A)
8.05
(71.56)
788.94% Details
9/10/2018 Neurocrine Bio. NBIX New Coverage Overweight
(N/A)
121.30
(134.66)
11.01% Details
9/10/2018 Exelixis EXEL New Coverage Underweight
(N/A)
18.55
(24.76)
33.48% Details
9/10/2018 Alder Biopharm ALDR New Coverage Underweight
(N/A)
18.10
(10.06)
-44.42% Details
9/10/2018 MyoKardia MYOK New Coverage Overweight
(N/A)
61.50
(224.91)
265.71% Details